Dana Dabelea, MD, PhD, Receives American Diabetes Association’s Kelly West Award for Outstanding Achievement in Epidemiology


Michelle Kirkwood

Arlington, Virginia
May 26, 2017

Dana Dabelea, MD, PhD, is the recipient of the American Diabetes Association® (Association) 2017  Kelly West Award for Outstanding Achievement in Epidemiology. This award recognizes significant contributions to the field of diabetes epidemiology. Dr. Dabelea will be recognized with this honor at the Association’s 77th Scientific Sessions®, June 9-13, 2017, at the San Diego Convention Center. She will deliver the Kelly West Award Lecture titled, “Diabetes in Youth: Looking Backwards to Inform the Future,” on Sunday, June 11.

Dr. Dabelea is Conrad Riley Endowed Professor at the Colorado School of Public Health. Her body of work is cited in more than 200 publications. Among her most noteworthy findings, Dr. Dabelea has described increases in prevalence and incidence of both type 1 and type 2 diabetes among youth in the U.S. She continues efforts to characterize the multiple complications of diabetes in a cohort of youth, including multiple minorities. Her research supports the pursuit of long-term life course approaches to reducing the burden of diabetes. For example, she has found that breast feeding ameliorates increased adiposity of offspring born to mothers with gestational diabetes, offering a transgenerational prevention strategy.

“Congratulations, Dr. Dabelea, on this achievement, and thank you for your impressive contributions to diabetes epidemiology,” said the Association’s President of Health Care and Education Brenda Montgomery, RN, MSHS, CDE¹. “Your research continues to offer a critical understanding of the diabetes epidemic in youth.”

Dr. Dabelea is a principal investigator on nine current federally funded grants and she co-chairs the SEARCH for Diabetes in Youth study. Beyond her scientific findings, she is committed to expanding the pipeline of well-trained scientists in diabetes epidemiology through mentorship.

The Kelly West Award for Outstanding Achievement in Epidemiology is supported by an unrestricted educational grant from Merck.

The American Diabetes Association’s 77th Scientific Sessions, to be held June 9-13, 2017, at the San Diego Convention Center, is the world’s largest scientific meeting focused on diabetes research, prevention and care. During the five-day meeting, health care professionals have exclusive access to more than 2,500 original research presentations, participate in provocative and engaging exchanges with leading diabetes experts, and can earn Continuing Medical Education (CME) or Continuing Education (CE) credits for educational sessions. The program is grouped into eight interest areas: Acute and Chronic Complications; Behavioral Medicine, Clinical Nutrition, Education and Exercise; Clinical Diabetes/Therapeutics; Epidemiology/Genetics; Immunology/Transplantation; Insulin Action/Molecular Metabolism; Integrated Physiology/Obesity; and Islet Biology/Insulin Secretion. Brenda Montgomery, RN, MSHS, CDE, President of Health Care and Education, will deliver her address on Saturday, June 10, and Alvin C. Powers, MD, President of Medicine and Science, will present his address on Sunday, June 11. Eight abstracts were selected by the Scientific Sessions Meeting Planning Committee to be presented on Tuesday, June 13, in the President’s Oral Session. These abstracts represent important research being conducted in the field of diabetes today. In total, the 2017 Scientific Sessions includes 378 abstracts in 49 oral sessions; 2,152 poster presentations including 50 moderated poster discussions; and 360 published-only abstracts.

About the American Diabetes Association

Nearly half of American adults have diabetes or prediabetes; more than 30 million adults and children have diabetes; and every 21 seconds, another individual is diagnosed with diabetes in the U.S. Founded in 1940, the American Diabetes Association (ADA) is the nation’s leading voluntary health organization whose mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. The ADA drives discovery by funding research to treat, manage and prevent all types of diabetes, as well as to search for cures; raises voice to the urgency of the diabetes epidemic; and works to safeguard policies and programs that protect people with diabetes. In addition, the ADA supports people living with diabetes, those at risk of developing diabetes, and the health care professionals who serve them through information and programs that can improve health outcomes and quality of life. For more information, please call the ADA at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. Find us on Facebook (American Diabetes Association), Twitter (@AmDiabetesAssn) and Instagram (@AmDiabetesAssn)

1 Disclosures for Brenda Montgomery. Employer: AstraZeneca Pharmaceuticals. Montgomery's role as President, Health Care & Education of the American Diabetes Association (Association) is a voluntary position to which she was elected by the members of the Association in 2015. She continues to recuse herself from any and all discussions, decisions or votes that have or could be perceived as having a conflict of interest with her employer.